Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 1;17(4):4899–4908. doi: 10.3892/mmr.2018.8535

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — Targeting MTA2 suppresses the growth and aggressiveness of non-small cell lung carcinoma cells. (A) Affinity of AbMTA2 with MTA2 as determined by ELISA analysis. (B) Immunofluorescence and western blotting experiments analyzed the efficiency of AbMTA2 targeting for MTA. Magnification, ×200. (C) Expression of MTA2 target genes in A549 cells. (D) Migration of A549 cells following treatment with AbMTA2. Magnification, ×400. (E) Invasion of A549 cells following treatment with AbMTA2. Magnification, ×400. (F) Apoptotic resistance of A549 cells following treatment with AbMTA2. The data are presented as the mean ± standard error of the mean of three independent experiments. **P<0.01. MTA2, metastasis associated protein MTA2; siRNA, small interfering RNA; MMP-2, 72 kDa type IV collagenase; MMP-9, matrix metalloproteinase-9; CT-1, cardiotrophin-1; FIB, rRNA 2′-O-methyltransferase fibrillarin; Ab, antibody.

Figure 2. — Targeting MTA2 suppresses the growth and aggressiveness of non-small cell lung carcinoma cells. (A) Affinity of AbMTA2 with MTA2 as determined by ELISA analysis. (B) Immunofluorescence and western blotting experiments analyzed the efficiency of AbMTA2 targeting for MTA. Magnification, ×200. (C) Expression of MTA2 target genes in A549 cells. (D) Migration of A549 cells following treatment with AbMTA2. Magnification, ×400. (E) Invasion of A549 cells following treatment with AbMTA2. Magnification, ×400. (F) Apoptotic resistance of A549 cells following treatment with AbMTA2. The data are presented as the mean ± standard error of the mean of three independent experiments. **P<0.01. MTA2, metastasis associated protein MTA2; siRNA, small interfering RNA; MMP-2, 72 kDa type IV collagenase; MMP-9, matrix metalloproteinase-9; CT-1, cardiotrophin-1; FIB, rRNA 2′-O-methyltransferase fibrillarin; Ab, antibody.